These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21116263)

  • 61. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
    Wilson JL; Nayanar V; Walker JS
    Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Blockade effect of mu and kappa opioid antagonists on the anti-nociception induced by intra-periaqueductal grey injection of oxytocin in rats.
    Ge Y; Lundeberg T; Yu LC
    Brain Res; 2002 Feb; 927(2):204-7. PubMed ID: 11821014
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Assessment of narcotic antagonists in the treatment of opioid dependence.
    Resnick RB; Schuyten-Resnick E; Washton AM
    Annu Rev Pharmacol Toxicol; 1980; 20():463-74. PubMed ID: 6992703
    [No Abstract]   [Full Text] [Related]  

  • 64. Sex differences in the modulation of mouse nest building behavior by kappa opioid receptor signaling.
    Jacobson ML; Wulf HA; Tsuda MC; Browne CA; Lucki I
    Neuropharmacology; 2020 Oct; 177():108254. PubMed ID: 32726598
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
    Neumeyer JL; Bidlack JM; Zong R; Bakthavachalam V; Gao P; Cohen DJ; Negus SS; Mello NK
    J Med Chem; 2000 Jan; 43(1):114-22. PubMed ID: 10633042
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Buprenorphine-containing treatments: place in the management of opioid addiction.
    Robinson SE
    CNS Drugs; 2006; 20(9):697-712. PubMed ID: 16953647
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of Chronic Social Defeat Stress on Sleep and Circadian Rhythms Are Mitigated by Kappa-Opioid Receptor Antagonism.
    Wells AM; Ridener E; Bourbonais CA; Kim W; Pantazopoulos H; Carroll FI; Kim KS; Cohen BM; Carlezon WA
    J Neurosci; 2017 Aug; 37(32):7656-7668. PubMed ID: 28674176
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving.
    Heidbreder CA; Hagan JJ
    Curr Opin Pharmacol; 2005 Feb; 5(1):107-18. PubMed ID: 15661634
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.
    Bruchas MR; Land BB; Chavkin C
    Brain Res; 2010 Feb; 1314():44-55. PubMed ID: 19716811
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pathological gambling: focusing on the addiction, not the activity.
    Tamminga CA; Nestler EJ
    Am J Psychiatry; 2006 Feb; 163(2):180-1. PubMed ID: 16449466
    [No Abstract]   [Full Text] [Related]  

  • 71. Pharmacotherapy II: narcotic and narcotic-antagonists analgesics.
    Gardier RW
    Dent Clin North Am; 1978 Jan; 22(1):125-41. PubMed ID: 23324
    [No Abstract]   [Full Text] [Related]  

  • 72. The endogenous opioid system: a common substrate in drug addiction.
    Trigo JM; Martin-García E; Berrendero F; Robledo P; Maldonado R
    Drug Alcohol Depend; 2010 May; 108(3):183-94. PubMed ID: 19945803
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Co-administration of opioid agonists and antagonists in addiction and pain medicine.
    Leri F
    Expert Opin Pharmacother; 2008 Jun; 9(8):1387-96. PubMed ID: 18473712
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Enadoline discrimination in squirrel monkeys: effects of opioid agonists and antagonists.
    Carey GJ; Bergman J
    J Pharmacol Exp Ther; 2001 Apr; 297(1):215-23. PubMed ID: 11259547
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The effects of morphine, naloxone, and κ opioid manipulation on endocrine functioning and social behavior in monogamous titi monkeys (Callicebus cupreus).
    Ragen BJ; Maninger N; Mendoza SP; Bales KL
    Neuroscience; 2015 Feb; 287():32-42. PubMed ID: 25485481
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pentazocine-induced antinociception is mediated mainly by μ-opioid receptors and compromised by κ-opioid receptors in mice.
    Shu H; Hayashida M; Arita H; Huang W; Zhang H; An K; Wu G; Hanaoka K
    J Pharmacol Exp Ther; 2011 Aug; 338(2):579-87. PubMed ID: 21543510
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacological adjuncts in the treatment of opiate dependence.
    Resnick RB
    Arch Invest Med (Mex); 1974; 5 SUPPL 1():235-44. PubMed ID: 4447422
    [No Abstract]   [Full Text] [Related]  

  • 78. A range of research-based pharmacotherapies for addiction.
    O'Brien CP
    Science; 1997 Oct; 278(5335):66-70. PubMed ID: 9311929
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242).
    Verhoest PR; Basak AS; Parikh V; Hayward M; Kauffman GW; Paradis V; McHardy SF; McLean S; Grimwood S; Schmidt AW; Vanase-Frawley M; Freeman J; Van Deusen J; Cox L; Wong D; Liras S
    J Med Chem; 2011 Aug; 54(16):5868-77. PubMed ID: 21744827
    [TBL] [Abstract][Full Text] [Related]  

  • 80. kappa-opioid regulation of neuronal activity in the rat supraoptic nucleus in vivo.
    Brown CH; Ludwig M; Leng G
    J Neurosci; 1998 Nov; 18(22):9480-8. PubMed ID: 9801385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.